CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

FLT3 LigandWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (7)

Name (Synonyms) Correlation
drug2508 SBRT Wiki 1.00
drug3176 anti-CD40 antibody Wiki 1.00
drug757 Convalescent Plasma Transfusion Wiki 0.71
drug1433 Interferon Beta-1A Wiki 0.50
drug812 DAS181 Wiki 0.41
drug1489 Ivermectin Wiki 0.22
drug1284 Hydroxychloroquine Wiki 0.10

Correlated MeSH Terms (2)

Name (Synonyms) Correlation
D002289 Carcinoma, Non-Small-Cell Lung NIH 0.71
D008175 Lung Neoplasms NIH 0.45

Correlated HPO Terms (2)

Name (Synonyms) Correlation
HP:0030358 Non-small cell lung carcinoma HPO 0.71
HP:0100526 Neoplasm of the lung HPO 0.45

There is one clinical trial.

Clinical Trials

1 FLT3 Ligand, CD40 Agonist Antibody, and Stereotactic Radiotherapy Versus Standard Therapy for Advanced Non-small Cell Lung Cancer: A Phase I/II Randomized Trial

The purpose of this study is to test a new way of treating the most common form of lung cancer. The investigators are testing a combination of radiotherapy with two new forms of immunotherapy. This study is testing the safety and effectiveness of this treatment approach as compared to standard treatment options.

NCT04491084 Non Small Cell Lung Cancer Lung Cancer Drug: FLT3 Ligand Biological: anti-CD40 antibody Radiation: SBRT
MeSH:Lung Neoplasms Carcinoma, Non-Small-Cell Lung
HPO:Neoplasm of the lung Non-small cell lung carcinoma

Primary Outcomes

Description: Death Any ≥ Grade 3 non-hematological toxicity, with the following exceptions: Grade 3 alopecia, vitiligo, or endocrinopathies controlled by hormone replacement therapy Grade 3 nausea that resolves to ≤ grade 2 with or without treatment within 72 hours Grade 3 vomiting and diarrhea that resolves to ≤ grade 2 with or without treatment within 72 hours Grade 3 fatigue that resolves to ≤ grade 2 within 5 days Grade 3 hypertension in the absence of maximal medical therapy Grade 3 adverse event of tumor flare (defined as local pain, irritation, or rash localized at sites of known or suspected tumor) of ≤ 7 days in duration Grade 3 amylase or lipase abnormalities that are not associated with symptoms or clinical manifestations of pancreatitis. It is recommended to consult with the Principal Investigator for grade 4 amylase or lipase abnormalities Grade 3 clinically significant laboratory abnormalities that are asymptomatic and can be reversed within 72 hours, however: Any Grade 4

Measure: Phase I: Dose-limiting toxicity (DLT), defined as follows:

Time: up to 8 weeks after initiation of study therapy

Measure: Phase II: Progression-free survival (PFS) duration

Time: defined as time from study registration until disease progression (scored using iRECIST) or death, whichever comes first up to 51 weeks.

Secondary Outcomes

Description: Length of time that patient survives from time of study registration

Measure: Overall survival (OS) duration

Time: From date of registration until the date of death from any cause, assessed up to 2 years

Description: The clinical benefit rate (CBR) will be defined as the percentage of subjects who achieve best response of confirmed CR or PR, or stable disease (SD) for at least four months.

Measure: Radiographic responses using descriptive statistics

Time: From date of registration, assessed up to 4 months

Description: Summary statistics (mean, standard deviation, median, 25th and 75th percentiles, and range) and the mean change from baseline of linear-transformed scores will be reported for all the items and subscales of the EORTC QLQ-C30 questionnaire and the QLQ-LC13, according to the EORTC scoring manual guidelines. higher scores are a better level of functioning

Measure: Quality of Life using EORTC QLQ-LC13 (quality of Life Questionnaire, Lung Cancer)

Time: 1 year

Description: Summary statistics (mean, standard deviation, median, 25th and 75th percentiles, and range) and the mean change from baseline of linear-transformed scores will be reported for all the items and subscales of the EORTC QLQ-C30 questionnaire and the QLQ-LC13, according to the EORTC scoring manual guidelines. Most items are scored 1 to 4, higher scores are a better level of functioning.

Measure: Quality of Life using QLQ-C30 (Quality of Life Questionnaire)

Time: 1 year

Description: Average daily step counts

Measure: Daily step count using descriptive statistics

Time: 1 year

Related HPO nodes (Using clinical trials)

HP:0100526: Neoplasm of the lung
Genes 62
ERCC6 PRKN SFTPA2 IRF1 EGFR SLC22A18 FASLG TSC2 NAB2 KEAP1 DICER1 TSC1 REST TRPV3 CYP2A6 TSC1 TSC2 PTEN WRN STK11 C11ORF95 TSC1 MAP3K8 BAP1 ERBB2 POU6F2 MBTPS2 RELA PPP2R1B SLCO2A1 SFTPC TSC1 H19 TP53 DIS3L2 PERP CASP8 PDGFRB RB1 EWSR1 STAT6 KRAS MUC5B TRIM28 TERT NOTCH3 DICER1 GPC3 WT1 TRIP13 HPGD WT1 WT1 AKT1 PIK3CA TP53 TSC2 TRIM28 LMNA BRCA2 DICER1 BRAF
Protein Mutations 52
C1156Y C797S D594G F1174C F1174V G1202R G1269A G12C G12D G469A G719A G719C G719S G776C G776V I10A L1196M L1198F L523S L755S L833F L8585R L858R L859R L861G L861Q L861R N375S P13K P4503A R776G R831C S1400A S1400C S1400D S1400E S1400F S1400G S1400I S1400K S1800A S1900A S1900C S1900D S768I T790M T81C T890M V600E V769L V777L V843I
SNP 6
rs1047768 rs10937405 rs11045585 rs12762549 rs4488809 rs751402
HP:0030358: Non-small cell lung carcinoma
Genes 3
TP53 BAP1 TP53
Protein Mutations 43
C797S C8092A D594G F1174C F1174V G1202R G1269A G12C G12D G12V G13D G2032R G469A G719A G719C G719S G776C G776V I10A L1196M L523S L755S L833F L8585R L858R L861G L861Q L861R P13K P4503A R776G R831C S1800A S1900A S1900C S768I T790M T81C V600E V600K V769L V777L V843I
SNP 2
rs1047768 rs751402